Assembly Biosciences
ASMB · NASDAQ
$21.19+$1.03 (+5.11%)TodayMarket closed ·
Prev close $20.16
EPS: actual vs estimate
Beat the estimate in 8 of the last 8 quarters, by 80.5% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.6596 | -$0.20 | +69.7% |
| Q1 FY26 | -$0.5814 | -$0.54 | +7.1% |
| Q4 FY25 | -$0.663 | $2.48 | +474.1% |
| Q3 FY25 | -$0.7902 | -$0.72 | +8.9% |
| Q2 FY25 | -$1.39 | -$1.33 | +4.5% |
| Q1 FY25 | -$1.63 | -$1.17 | +28.3% |
| Q4 FY24 | -$2.08 | -$1.57 | +24.5% |
| Q3 FY24 | -$2.06 | -$1.51 | +26.7% |
Earnings calls
- Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Bank of America Global Healthcare Conference 2026
- Special Call - Assembly Biosciences, Inc.
- Special Call - Assembly Biosciences, Inc.
- Special Call - Assembly Biosciences, Inc.
- Special Call - Assembly Biosciences, Inc.
- Shareholder/Analyst Call - Assembly Biosciences, Inc.
- ASMB - Assembly Biosciences, Inc. (ASMB) CEO on Hepatitis B Program Update Call Transcript
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.